−6.2058USD
−8.16 MUSD
5.82 MUSD
4.10 M
About Petros Pharmaceuticals, Inc.
Sector
CEO
Shulman John David
Headquarters
New York
Website
Employees (FY)
21
ISIN
US71678J2096
FIGI
BBG00TYL0TW3
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PTPI is 0.6979 USD — it has increased by 1.14% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Petros Pharmaceuticals, Inc. stocks are traded under the ticker PTPI.
Petros Pharmaceuticals, Inc. is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
PTPI stock is 11.81% volatile and has beta coefficient of 2.56. Check out the list of the most volatile stocks — is Petros Pharmaceuticals, Inc. there?
One year price forecast for Petros Pharmaceuticals, Inc. has a max estimate of 4.0000 USD and a min estimate of 4.0000 USD.
Yes, you can track Petros Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
PTPI stock has fallen by 20.24% compared to the previous week, the month change is a 53.78% fall, over the last year Petros Pharmaceuticals, Inc. has showed a 85.76% decrease.
PTPI net income for the last quarter is −4.55 M USD, while the quarter before that showed −2.55 M USD of net income which accounts for −78.64% change. Track more Petros Pharmaceuticals, Inc. financial stats to get the full picture.
Today Petros Pharmaceuticals, Inc. has the market capitalization of 4.74 M, it has increased by 171.89% over the last week.
No, PTPI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PTPI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Petros Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 21.00 employees. See our rating of the largest employees — is Petros Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Petros Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Petros Pharmaceuticals, Inc. stock shows the sell signal. See more of Petros Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Petros Pharmaceuticals, Inc. future price: according to them, PTPI price has a max estimate of 4.00 USD and a min estimate of 4.00 USD. Read a more detailed Petros Pharmaceuticals, Inc. forecast: see what analysts think of Petros Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Petros Pharmaceuticals, Inc. EBITDA is −6.33 M USD, and current EBITDA margin is −126.19%. See more stats in Petros Pharmaceuticals, Inc. financial statements.